Table 3.
Clinical Outcomes by Line of Therapy
| Index Line (N = 187) | All Treatment Lines After Initial FL Diagnosis | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1L (n = 187) | 2L (n = 187) | 3L (n = 187) | 4L (n = 147) | 5L (n = 96) | 6L (n = 70) | 7L (n = 44) | ≥8L (n = 51) a | |||||||||||
| Best clinical response | ||||||||||||||||||
| CR, n (%) | 73 | 39.0 | 71 | 38.0 | 56 | 30.0 | 70 | 37.4 | 47 | 32.0 | 21 | 21.9 | 13 | 18.6 | 7 | 15.9 | 10 | 19.6 |
| PR, n (%) | 59 | 31.6 | 61 | 32.6 | 54 | 28.9 | 60 | 32.1 | 43 | 29.3 | 23 | 24.0 | 21 | 30.0 | 8 | 18.2 | 11 | 21.6 |
| ORR, n (%) | 132 | 70.6 | 132 | 70.6 | 110 | 58.8 | 130 | 69.5 | 90 | 61.2 | 44 | 45.8 | 34 | 48.6 | 15 | 34.1 | 21 | 41.2 |
| TNT-D | ||||||||||||||||||
| n, % censored | 37 | 19.8 | − | − | − | − | 30 | 16.0 | 36 | 24.5 | 16 | 16.7 | 11 | 15.7 | 11 | 25.0 | 10 | 19.6 |
| Median, mo (95% CI) | 14.6 (11.8-18.6) | 19.9 (16.0-23.3) | 13.8 (10.5-16.1) | 12.9 (10.9-17.6) | 13.2 (11.3-19.0) | 10.1 (7.3-13.1) | 7.9 (5.2-14.0) | 5.3 (3.0-7.4) | 5.8 (3.0-7.1) | |||||||||
| EFS | ||||||||||||||||||
| n, % censored | 36 | 19.3 | − | − | − | − | 29 | 15.5 | 34 | 23.1 | 16 | 16.7 | 10 | 14.3 | 9 | 20.5 | 9 | 17.6 |
| Median, mo (95% CI) | 14.4 (11.0-18.0) | 18.1 (14.9-22.2) | 13.0 (10.2-14.9) | 11.8 (10.1-16.6) | 12.0 (10.7-16.0) | 9.4 (6.8-13.1) | 6.9 (4.9-13.3) | 3.7 (2.1-6.1) | 4.4 (1.7-5.9) | |||||||||
| 18-mo EFS rate, % | 44.2 | 51.3 | 36.9 | 40.4 | 41.6 | 32.5 | 23.3 | 16.2 | 16.9 | |||||||||
| OS | ||||||||||||||||||
| n, % censored | 114 | 61.0 | 114 | 61.0 | 114 | 61.0 | 114 | 61.0 | 84 | 57.1 | 48 | 50.0 | 32 | 45.7 | 21 | 47.7 | 15 | 29.4 |
| Median, mo (95% CI) | 128.0 (78.1-NR) | 182.3 (147.9-NR) | 150.5 (103.6-236.8) | 133.7 (78.1-232.4) | 95.8 (51.9-134.9) | 46.3 (31.7-76.5) | 30.1 (16.4-50.3) | 26.6 (10.0-45.7) | 11.4 (5.9-21.2) | |||||||||
| 18-mo OS rate, % | 92.4 | 99.5 | 97.9 | 93.5 | 88.7 | 85.7 | 74.1 | 60.9 | 44.4 | |||||||||
aDue to small sample sizes in later therapy lines, 8L+ consolidates all lines of therapy from 8L or later and includes repeated observations for some patients.
1L = first line; 2L = second line; 3L = third line; 4L = fourth line; 5L = fifth line; 6L = sixth line; 7L = seventh line; 8L = eighth line; CR = complete response; EFS = event-free survival; FL = follicular lymphoma; NR = not reached; ORR = overall response rate; OS = overall survival; PR = partial response; TNT-D = time to next treatment or death.